August 20, 2024
It's been over four years since clinical trials began for COVID-19 vaccines, and while the shots have helped the pandemic recede, the lucrative technology has spurred numerous patent suits, many of which are still in the early stages. Here's a look at some of the key cases in the U.S.
August 25, 2023
Alnylam Pharmaceuticals Inc. and Moderna Inc. on Friday agreed to a final judgment of noninfringement in Alnylam's lawsuit alleging Moderna used patented biotechnology for its Spikevax coronavirus vaccine, following a Delaware federal judge's claim construction ruling, which Alnylam has vowed to appeal.
May 12, 2023
Drugmaker Moderna has fired back at patent litigation lodged against it by a competitor last year over purportedly poached biotechnology in its coronavirus vaccine known as Spikevax, arguing that the asserted inventions are invalid and the infringement claims can't hold up in light of safe harbor protections.
April 26, 2023
A Delaware federal judge on Wednesday swiftly rejected a request from pharmaceutical giant Moderna Inc. to toss patent infringement claims by Alnylam Pharmaceuticals Inc. over its COVID-19 vaccine, calling the request "premature."
May 23, 2022
Moderna Inc. urged a Delaware federal court to nix several claims from an infringement suit claiming it used technology Alnylam Pharmaceuticals Inc. developed that ensures the mRNA in COVID-19 vaccines safely enters the body, arguing Monday that the claims belong in the U.S. Court of Federal Claims.
March 17, 2022
Alnylam Pharmaceuticals hit Moderna and Pfizer with separate patent infringement lawsuits Thursday, claiming they use technology it developed that ensures the mRNA in their COVID-19 vaccines safely enters the body.